 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Neurogen Corporation
 |
Neurogen Corporation |
 |
 |
 |
PROFILE |
 |
Neurogen is a development-stage pharmaceuticals company specializing in the discovery and development of drugs to treat psychiatric, metabolic, and inflammatory disorders by regulating nerve cell communications in the brain. Working with Pfizer, the firm is developing its lead anxiety drug candidate, NGD 91-3. It is also working with Pfizer on treatments for Alzheimer's disease and obesity, as well as for canine and feline stress, obesity, and cognitive dysfunction. Neurogen has discovered possible therapies for depression, stress, pain, and inflammation through its Accelerated Intelligent Drug Discovery (AIDD) technology platform; the company licenses AIDD to other drug companies to help fund its own research.
COMPETITION |
 |
Neurobiological Technologies, Inc. (NTII)
Pharmacia Corporation (PHA)
Synaptic Pharmaceutical Corporation (SNAP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 20.40
1-Yr. Sales Growth: 100.0%
Employees: 187
Revenue per employee: $109,090.91
KEY PEOPLE |
 |
Harry H. Penner
CEO
Stephen R. Davis
CFO
CONTACT INFO |
 |
35 NE Industrial Rd.
Branford, CT 06405
US
Phone: 203-488-8201
Fax: 203-481-8683
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |